WO2002047722A1 - Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof - Google Patents
Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof Download PDFInfo
- Publication number
- WO2002047722A1 WO2002047722A1 PCT/JP2001/010956 JP0110956W WO0247722A1 WO 2002047722 A1 WO2002047722 A1 WO 2002047722A1 JP 0110956 W JP0110956 W JP 0110956W WO 0247722 A1 WO0247722 A1 WO 0247722A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nonpeptidyl
- antagonist
- gonadotropin
- releasing hormone
- medicinal compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002221139A AU2002221139A1 (en) | 2000-12-15 | 2001-12-14 | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000382431 | 2000-12-15 | ||
JP2000-382431 | 2000-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002047722A1 true WO2002047722A1 (en) | 2002-06-20 |
Family
ID=18850254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010956 WO2002047722A1 (en) | 2000-12-15 | 2001-12-14 | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002221139A1 (en) |
WO (1) | WO2002047722A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003002092A3 (en) * | 2001-06-29 | 2003-04-10 | Takeda Chemical Industries Ltd | Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
WO2004067535A1 (en) * | 2003-01-29 | 2004-08-12 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
US8921326B2 (en) | 2006-12-18 | 2014-12-30 | Takeda Pharmaceutical Company Limited | Sustained-release composition and method for producing the same |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0626170A2 (en) * | 1993-05-10 | 1994-11-30 | Sandoz Ltd. | Stabilisation of pharmacologically active compounds in sustained release compositions |
WO1995015767A1 (en) * | 1993-12-09 | 1995-06-15 | Asta Medica Aktiengesellschaft | Long-acting injection suspensions and a process for their preparation |
WO1995028405A1 (en) * | 1994-04-19 | 1995-10-26 | Takeda Chemical Industries, Ltd. | Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists |
WO1996024597A1 (en) * | 1995-02-08 | 1996-08-15 | Takeda Chemical Industries, Ltd. | Thienopyrimidine derivatives, their production and use |
WO1998032423A1 (en) * | 1997-01-29 | 1998-07-30 | Takeda Chemical Industries, Ltd. | Sustained-release microspheres, their production and use |
WO1999036099A1 (en) * | 1998-01-16 | 1999-07-22 | Takeda Chemical Industries, Ltd. | Sustained release compositions, process for producing the same and utilization thereof |
WO2000056739A1 (en) * | 1999-03-24 | 2000-09-28 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
JP2001081043A (en) * | 1999-07-15 | 2001-03-27 | Takeda Chem Ind Ltd | Sustained release composition, its production and use |
-
2001
- 2001-12-14 AU AU2002221139A patent/AU2002221139A1/en not_active Abandoned
- 2001-12-14 WO PCT/JP2001/010956 patent/WO2002047722A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0626170A2 (en) * | 1993-05-10 | 1994-11-30 | Sandoz Ltd. | Stabilisation of pharmacologically active compounds in sustained release compositions |
WO1995015767A1 (en) * | 1993-12-09 | 1995-06-15 | Asta Medica Aktiengesellschaft | Long-acting injection suspensions and a process for their preparation |
WO1995028405A1 (en) * | 1994-04-19 | 1995-10-26 | Takeda Chemical Industries, Ltd. | Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists |
WO1996024597A1 (en) * | 1995-02-08 | 1996-08-15 | Takeda Chemical Industries, Ltd. | Thienopyrimidine derivatives, their production and use |
WO1998032423A1 (en) * | 1997-01-29 | 1998-07-30 | Takeda Chemical Industries, Ltd. | Sustained-release microspheres, their production and use |
WO1999036099A1 (en) * | 1998-01-16 | 1999-07-22 | Takeda Chemical Industries, Ltd. | Sustained release compositions, process for producing the same and utilization thereof |
WO2000056739A1 (en) * | 1999-03-24 | 2000-09-28 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
JP2001081043A (en) * | 1999-07-15 | 2001-03-27 | Takeda Chem Ind Ltd | Sustained release composition, its production and use |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067030B2 (en) | 2001-06-29 | 2011-11-29 | Takeda Pharmaceutical Company Limited | Controlled release composition and method of producing the same |
US8815801B2 (en) | 2001-06-29 | 2014-08-26 | Takeda Pharmaceutical Company Limited | Controlled release composition and method of producing the same |
EP1491236A1 (en) * | 2001-06-29 | 2004-12-29 | Takeda Chemical Industries, Ltd. | Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
US8246987B2 (en) | 2001-06-29 | 2012-08-21 | Takeda Pharmaceutical Company Limited | Controlled release composition and method of producing the same |
WO2003002092A3 (en) * | 2001-06-29 | 2003-04-10 | Takeda Chemical Industries Ltd | Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
US7429559B2 (en) | 2001-06-29 | 2008-09-30 | Takeda Pharmaceutical Company Limited | Controlled release composition and method of producing the same |
EP1949936A3 (en) * | 2001-06-29 | 2008-10-08 | Takeda Pharmaceutical Company Limited | Controlled release composition and method of producing the same |
CN100360538C (en) * | 2003-01-29 | 2008-01-09 | 武田药品工业株式会社 | Thienopyrimidine compound and use of the same |
US8058280B2 (en) | 2003-01-29 | 2011-11-15 | Takeda Pharmaceutical Company Limited | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
US7300935B2 (en) | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
US8735401B2 (en) | 2003-01-29 | 2014-05-27 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
WO2004067535A1 (en) * | 2003-01-29 | 2004-08-12 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
US9346822B2 (en) | 2003-01-29 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
US8921326B2 (en) | 2006-12-18 | 2014-12-30 | Takeda Pharmaceutical Company Limited | Sustained-release composition and method for producing the same |
US9617303B2 (en) | 2006-12-18 | 2017-04-11 | Takeda Pharmaceutical Company Limited | Sustained-release composition and method for producing the same |
US9713595B2 (en) | 2006-12-18 | 2017-07-25 | Takeda Pharmaceuticals Company Limited | Sustained-release composition and method for producing the same |
Also Published As
Publication number | Publication date |
---|---|
AU2002221139A1 (en) | 2002-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7939298A (en) | An itraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same | |
AU8142594A (en) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | |
HK1038699A1 (en) | Aqueous process for manufacturing paroxetine solid dispersions | |
CA2396159A1 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
EP1203766B8 (en) | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | |
CA2386516A1 (en) | Multilayered liquid composition | |
WO2002045571A3 (en) | Fast dissolving tablet | |
AU2001278696A1 (en) | Aqueous pharmaceutical compositions | |
HK1092485A1 (en) | Method of manufacture of polyacrolein | |
CO5440227A1 (en) | ANTIHELMITIC AND INJECTABLE COMPOSITION IMPROVED GROWTH | |
WO2002014403A3 (en) | Acid end group poly(d,l-lactide-co-glycolide) copolymers with high glycolide content | |
WO2000041528A3 (en) | Improved controlled release compositions and method | |
CA2290893A1 (en) | Magnesium omeprazole | |
WO2006010155A3 (en) | Gonadotropin releasing hormone antagonists | |
WO2002047722A1 (en) | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof | |
CA2393757A1 (en) | Cycloamine ccr5 receptor antagonists | |
EP1285660A4 (en) | Zinc-supplementary compositions for oral administration | |
ID26346A (en) | PROCESS OF MAKING 5-HYDROXYBENZO ACID (b) TIOFEN-3-CARBOXICATE | |
AU3550100A (en) | Biodegradable, injectable oligomer-polymer composition | |
WO2001003666A3 (en) | Liquid based vaso-occlusive compositions | |
AU9259501A (en) | Interphenylene 7-oxabicyclic(2.2.1)heptane oxazoles as prostaglandin F<sub>2alpha</sub> antagonists | |
RU99116432A (en) | METHOD FOR IMMOBILIZING PHYSIOLOGICALLY ACTIVE COMPOUNDS | |
AU2002215169A1 (en) | Sanitizing composition containing chlorinated isocyanurate for in-ovo injection equipment | |
RU2002133182A (en) | COMPOSITION FOR THE DELIVERY OF A WATER-CONDENSATE MIXTURE FROM A WELL | |
AU4305300A (en) | Solid composition containing at least one surfactant with a low melting point |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |